Déborah Ducasse

Dr. Déborah Ducasse


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2017 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
DDDéborah Ducasse
Déborah Ducasse
GLGwenolé Loas
Gwenolé Loas
DDDéborah Dassa
Déborah Dassa
CGCarla Gramaglia
Carla Gramaglia
PZPatrizia Zeppegno
Patrizia Zeppegno
PCPhilippe Courtet
Philippe Courtet

27 June 2018 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
DDDéborah Ducasse
Déborah Ducasse
RHRonald R. Holden
Ronald R. Holden
LBLaurent Boyer
Laurent Boyer
SASylvaine Artero
Sylvaine Artero
RCRaffaella Calati
Raffaella Calati
EOEmilie Olié
Emilie Olié
It’s been proposed that psychological pain is at the core of the suicidal process, from ideation to attempts. In this meta-analysis, intensity of psychological pain was compared in individuals with and without suicidal ideation and attempts in order to quantify the association between psychological pain and suicide.

5 June 2015 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
PDF file
PCPhilippe Courtet
Philippe Courtet
LGLucas Giner
Lucas Giner
MSMaude Seneque
Maude Seneque
SGSébastien Guillaume
Sébastien Guillaume
EOEmilie Olie
Emilie Olie
DDDéborah Ducasse
Déborah Ducasse
Objectives. Suicidal behaviour (SB) entered the DSM-5, underlying a specific biological vulnerability. Then, recent findings suggested a possible role of the immune system in SB pathogenesis. The objective of this review is to present these main immune factors involved in SB pathogenesis. Methods. We conducted a review using Preferred Reporting Items for Systematic reviews and Meta-Analysis criteria, and combined (“Inflammation”) AND (“Suicidal ideation” OR “Suicidal attempt” OR “suicide”). Results. Post mortem studies demonstrated associations between suicide and inflammatory cytokines in the orbitofrontal cortex, a brain region involved in suicidal vulnerability. Also, microgliosis and monocyte–macrophage system activation may be a useful marker of suicide neurobiology. Kynurenine may influence inflammatory processes, and related molecular pathways may be involved in SB pathophysiology. Few recent studies associated inflammatory markers with suicidal vulnerability: serotonin dysfunction, impulsivity and childhood trauma. Interestingly, the perception of threat that leads suicidal individuals to contemplate suicide may activate biological stress responses, including inflammatory responses. Conclusions. Translational projects would be crucial to identify a specific marker in SB disorders, to investigate its clinical correlations, and the interaction between inflammatory cytokines and monoamine systems in SB. These researches might lead to new biomarkers and novel directions for therapeutic strategies.

1 May 2015 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
DDDéborah Ducasse
Déborah Ducasse
EOEmilie Olié
Emilie Olié
SGSébastien Guillaume
Sébastien Guillaume
SASylvaine Artero
Sylvaine Artero
PCPhilippe Courtet
Philippe Courtet

6 June 2018 in Psychotherapy and Psychosomatics
Verified
Journal Article
Closed access
PDF file
DDDéborah Ducasse
Déborah Ducasse
IJIsabelle Jaussent
Isabelle Jaussent
VAVéronique Arpon-Brand
Véronique Arpon-Brand
MVMarina Vienot
Marina Vienot
CLCamelia Laglaoui
Camelia Laglaoui
EOEmilie Olié
Emilie Olié
Background: The management of suicidal crisis remains a major issue for clinicians, driving the development of new strategies to improve suicide prevention. Methods: We conducted a randomized controlled trial comparing a 7-week acceptance and commitment therapy (ACT) versus relaxation group, as adjunct to treatment as usual for adult outpatients suffering from a current suicidal behavior disorder. The primary outcome was the rate of change in the Columbia Suicide Severity Rating Scale suicidal ideation subscore (adding severity and intensity subscores). Secondary outcomes were the rates of change for depressive symptomatology, psychological pain, anxiety, hopelessness, anger, quality of life, and therapeutic processes. Assessments were performed in the 2 weeks preceding the beginning of the treatment (pretreatment assessment), and within 1 week (posttherapy assessment) and 3 months (follow-up assessment) after therapy completion. Results: Forty adults were included and randomized. The rate of change in ACT for suicidal ideation at the posttherapy assessment was higher than in the relaxation group (β [SE] = –1.88 [0.34] vs. –0.79 [0.37], respectively; p = 0.03). ACT effectiveness remained stable at the 3-month follow-up. We found a similar pattern of change for depressive symptomatology and anxiety, psychological pain, hopelessness, anger, and quality of life. Therapeutic processes improved more in the ACT group than in the relaxation group. Treatment adherence was high in the ACT group, all participants reported satisfaction with the program. Conclusions: Through its effectiveness in reducing suicidal ideation and improving the clinical dimensions associated with suicidal risk in patients suffering from a suicidal behavior disorder, ACT could be developed as an adjunctive strategy in programs for suicide prevention.

1 October 2015 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
PCPh. Courtet
Ph. Courtet
IJI. Jaussent
I. Jaussent
CGC. Genty
C. Genty
ADanne marie dupuy
anne marie dupuy
SGSébastien Guillaume
Sébastien Guillaume
EOE. Olié
E. Olié